Hair Loss (Female) · Oral & Topical Formulations

Hair Loss Treatment · Female

Female pattern hair loss is hormonal too — just different hormones.

For women, pattern hair loss is driven by androgens (testosterone and DHT) binding to sensitive scalp follicles, causing them to miniaturize over time. The trigger is often a shift in hormone balance — perimenopause, postpartum, PCOS, or simply genetic susceptibility — that makes follicles more reactive to the androgens already in your body.

Spironolactone blocks androgen receptors at the follicle, preventing testosterone and DHT from binding and shrinking the hair. Minoxidil increases follicular blood flow and prolongs the growth phase of the hair cycle. Biotin supports keratin synthesis — the protein backbone of hair. Together, these actives address the hormonal driver, the follicular response, and the structural building blocks of new growth.

Obsidian Genetics offers three formulations for women: an oral capsule (Min/Spiro/Biotin) for systemic effect, plus two topical options — a Gentle (Min only) for sensitive scalps, and a Min-Free (Spiro-based) for women who can't tolerate minoxidil. Your provider matches the formulation to your hair-loss pattern, prior response, and contraception status.

Important: This formulation is for women only. Finasteride and dutasteride (the male-pattern-loss options) are contraindicated in women of childbearing potential. Postmenopausal women may also consider finasteride options off-label — see the Oral Hair Loss page.

Prescription required · Free shipping

Women's Hair Loss

Compounded prescription treatment for female pattern hair loss — choose your formulation below.

Choose Formulation

Compounded Oral Capsule

Minoxidil 1mg / Spironolactone 25mg / Biotin 5mg — once-daily compounded capsule

Choose Duration

1 Month Supply

$49 / month

Includes ongoing provider care & support
Compounded medication · Platform access

🛡️100% Online

🩺Board-Certified

📦Fast Shipping

The Evidence

Female pattern hair loss, by the numbers.

Both minoxidil and spironolactone are well-established in clinical practice for female pattern hair loss, with decades of off-label use and growing trial data.

~25%

Affected by age 49 Approximately 25% of women show clinical female pattern hair loss by age 49, rising to ~41% by age 69 (Norwood/Olsen-based prevalence data). Incidence peaks again around menopause.

88%

Spironolactone — stable or improved Sinclair et al. (2005) followed 80 women on spironolactone 200mg/day for female pattern hair loss; 44% improved and 44% remained stable at 12 months — 88% non-progression. Lower doses (25–50mg) have less evidence but a more favorable side-effect profile.

RCT

Low-dose oral minoxidil Randomized trials (Ramos et al. 2020; Vahabi-Amlashi et al.) show low-dose oral minoxidil (0.25–1mg daily) is comparably effective to topical 5% solution for female pattern hair loss, with fewer scalp side effects.

Dual

Two complementary mechanisms Spironolactone blocks androgen receptors (the hormonal driver) while minoxidil supports follicular blood flow and growth phase — addressing both cause and consequence

Female AGA prevalence — Vujovic & Del Marmol, Biomed Res Int. 2014; PMID 24812631 review of female pattern hair loss etiopathogenesis and diagnosis | Spironolactone 88% stable/improved — Sinclair et al., Br J Dermatol 2005; PMID 16029333; n=80 women, 200mg/day × 12 months. Meta-analytic data on combination therapy: PMID 37719557 reports ~57% improvement with monotherapy and ~66% with combined spiro+minoxidil therapy | Low-dose oral minoxidil RCTs — Ramos et al., J Am Acad Dermatol 2020; PMID 31707255 (1mg oral vs 5% topical in 52 women, comparable efficacy); systematic review with meta-regression: PMID 36138937 shows positive dose-dependent efficacy

Individual results vary. Spironolactone and low-dose oral minoxidil are both used off-label for female pattern hair loss in the United States. Compounded combination tablets are prepared by a licensed compounding pharmacy and are not FDA-approved as finished drug products. Sinclair 2005 used 200mg/day spironolactone; this compounded combination uses 25mg, which sits at the low end of the clinical dose range (25–200mg, mean ~100mg in published series) — your provider may adjust at follow-up. Results are not guaranteed.

How It Works

Two complementary mechanisms in one daily tablet.

Mechanism 01

Spironolactone — Androgen Receptor Blockade

Spironolactone competitively blocks androgen receptors at the hair follicle. Even with normal androgen levels, sensitive follicles miniaturize when androgens bind. By occupying the receptor, spironolactone reduces follicular sensitivity to testosterone and DHT — addressing the root hormonal driver of female pattern loss. At 25mg, you get meaningful anti-androgen effect with the lowest typical side-effect burden.

Mechanism 02

Minoxidil — Follicular Vasodilation

Minoxidil is a potassium channel opener that dilates the small blood vessels feeding hair follicles. Better blood flow means better oxygen and nutrient delivery to the hair bulb. It also extends the anagen (active growth) phase of the hair cycle, giving each hair more time to grow before shedding. Low-dose oral minoxidil (1mg here) achieves these effects with fewer scalp-irritation side effects than topical formulations.

Mechanism 03

Biotin — Keratin Synthesis Support

Biotin (vitamin B7) is an essential cofactor for keratin synthesis — the structural protein that hair is built from. Most people aren't biotin-deficient at baseline, but supplemental biotin is widely used as a hair-support nutrient and may help in subclinical deficiency states. Note: high-dose biotin (5mg here) can interfere with several immunoassay-based lab tests — stop biotin 48–72 hours before bloodwork and tell any clinician ordering labs that you're taking it.

Timeline & Expectations

What to expect month by month.

Months 1–3

Spironolactone starts blocking androgen receptors immediately. Minoxidil begins extending the growth phase. Some women experience a temporary increase in shedding in weeks 2–6 as the hair cycle synchronizes — this is normal and usually resolves. Do not stop treatment during this phase.

Months 3–6

Shedding phase resolves. Hair density begins to stabilize. The first signs of new growth — finer hairs along the part or thinning area — become visible. Energy and scalp sensitivity typically improve. Your provider may check blood pressure and potassium during this window.

Months 6–9

Visible density improvement. New hairs are thicker and longer than the miniaturized hairs they replaced. Many women report noticeable improvement in part width or coverage at the crown. Best estimate window for the most patient-reported satisfaction.

Month 12+

Full response achieved in most responders. Continued daily use maintains results. Like all hair loss treatments, stopping leads to gradual loss of benefit as androgen receptors re-engage and minoxidil's growth-phase support stops. Long-term use is the norm.

Important Information

Safety and what to monitor.

Spironolactone is a well-established medication with decades of clinical use. Both drugs in this tablet have known monitoring needs your provider will manage with you.

⚠ Important Safety Information

Pregnancy: Spironolactone is contraindicated in pregnancy — it can cause feminization of male fetuses. Women of childbearing potential must use reliable contraception while on this medication, and should stop immediately if pregnancy is possible. Potassium: Spironolactone is a potassium-sparing diuretic. Your provider will check baseline potassium and recheck periodically. Avoid potassium supplements and salt substitutes containing potassium unless your provider directs otherwise. Blood pressure: Both spironolactone and minoxidil can lower blood pressure; mild dizziness is possible, particularly in the first weeks. Drug interactions: ACE inhibitors, ARBs, NSAIDs, and lithium can interact with spironolactone — disclose all medications during intake. Kidney function: Disclose any history of kidney disease; baseline kidney function will be checked. Biotin lab interference: High-dose biotin (5mg) can cause falsely elevated or suppressed results on many immunoassay-based lab tests — including troponin (heart attack diagnosis), thyroid hormones (TSH/T4), vitamin D, parathyroid hormone, and reproductive hormones. Stop biotin at least 48–72 hours before any blood test and inform every clinician ordering bloodwork that you take biotin. The FDA issued a safety communication on this in 2017 (updated 2019).

Common, usually mild side effects: Breast tenderness or fullness (more common at higher spironolactone doses; usually mild at 25mg), menstrual irregularities (lighter, missed, or shifted cycles), mild diuretic effect (increased urination, particularly in the first weeks), mild fluid retention from minoxidil, possible mild increase in body hair (hypertrichosis) from minoxidil — usually subtle at 1mg. Less common: Headache, dizziness when standing quickly, mild fatigue. Rare but report immediately: Persistent palpitations, severe dizziness, significant swelling, signs of high potassium (muscle weakness, irregular heartbeat).

FREQ—
UENTLY
ASKED

Female pattern hair loss has two drivers — hormonal sensitivity (androgens binding the follicle) and reduced growth-phase support (poor follicular blood flow, shortened anagen). Minoxidil addresses the second; spironolactone addresses the first. Used alone, each helps a subset of women. Used together, they cover both mechanisms — and clinical practice supports the combination for patients who plateau on single-active regimens.

Spironolactone for hair loss is dosed 25–200mg daily across published studies, with the typical mean around 80–110mg. 25mg sits at the lowest end of the therapeutic range — intentionally, to maximize tolerability while still providing meaningful androgen-receptor blockade. Some studies show benefit at 25mg with substantially fewer side effects (breast tenderness, blood pressure changes, menstrual irregularities) than higher doses. If your response at 25mg is modest after 6 months, your provider may adjust the protocol. Patients who need stronger anti-androgen effect can step up from this dose.

No. Spironolactone is contraindicated in pregnancy because it can cause feminization of male fetuses. Women of childbearing potential must use reliable contraception while on the medication. If you are actively trying to conceive or pregnancy is possible, this formulation is not appropriate and you should discuss alternatives (such as topical-only options) with your provider.

Yes — your provider will check baseline potassium before starting and recheck periodically. Spironolactone is a potassium-sparing diuretic, meaning it can raise serum potassium. The risk is higher in people with kidney disease or those on ACE inhibitors, ARBs, NSAIDs, or potassium supplements. Disclose all medications and any kidney history during intake. Most patients tolerate the medication without issue, but monitoring is part of safe long-term use.

Hair growth is slow. Expect the first 4–8 weeks to feature a brief synchronized shedding phase (normal, do not stop). Stabilization of further loss is typical by month 3. Visible regrowth is usually noticeable by month 6, with the most pronounced improvement between months 6–12. The full response typically takes 12 months of consistent daily use. If you don't see improvement by month 6, talk to your provider about adjusting the protocol.

For sustained results, yes. The underlying biology of female pattern hair loss continues regardless of treatment. If you stop, the gains are gradually lost as androgen receptors re-engage and the minoxidil-supported growth phase shortens. Many women view daily oral hair-loss medication as a long-term investment in hair preservation — the routine becomes simple after the first few weeks.

Biotin (vitamin B7) is a cofactor in keratin synthesis — the protein hair is made from. Most people aren't deficient, but supplemental biotin at this dose (5mg / 5000 mcg) is commonly used in hair-support protocols. Important — lab test interference: the FDA issued a safety communication about high-dose biotin interfering with immunoassay-based lab tests, including troponin (heart attack), TSH/T4 (thyroid), 25-OH vitamin D, parathyroid hormone, and some hormone assays. Tell any clinician ordering bloodwork that you take biotin, and stop biotin at least 48–72 hours before lab tests. Without this disclosure, results can be falsely elevated or suppressed and lead to incorrect diagnoses.

Postmenopausal women have more options. This Min/Spiro combination remains a strong choice and avoids the teratogenicity concerns that constrain younger women. However, postmenopausal women can also be prescribed finasteride or other 5α-reductase inhibitors off-label — different mechanism, different side-effect profile, no androgen-receptor blockade. The right choice depends on your goals, tolerance for systemic anti-androgen effects (breast tenderness, blood pressure), and whether you have a strong family history of male pattern loss. Your provider will discuss both paths during intake. See also the Oral Hair Loss page for finasteride-based options.

Important: The oral capsule (Min 1mg / Spironolactone 25mg / Biotin 5mg) and the two topical formulations described on this page are compounded prescription products prepared by a licensed compounding pharmacy. Active ingredients are FDA-approved for various indications: minoxidil (hypertension; topical 5% for AGA), spironolactone (hypertension, heart failure, hyperaldosteronism), biotin (dietary supplement), latanoprost (glaucoma), hydrocortisone (inflammation/irritation), azelaic acid (rosacea, acne), caffeine (cosmetic), melatonin (sleep/cosmetic), and cetirizine/levocetirizine (allergies). Use for female pattern hair loss is off-label and prescribed at provider discretion following clinical review. Pregnancy: Spironolactone is contraindicated in pregnancy — it can cause feminization of male fetuses. Latanoprost can darken skin and alter eye color if applied near the eyes. Women of childbearing potential must use reliable contraception while on spironolactone-containing formulations. Lab test interference: high-dose biotin (5mg) can cause falsely elevated or suppressed immunoassay results — stop biotin 48–72 hours before any blood test and inform every clinician ordering bloodwork that you take biotin. Compounded combination tablets and topicals are not FDA-approved as finished drug products. Individual results vary; not all patients respond. Prescription required. All Obsidian Genetics prescriptions are issued following clinical review by a licensed provider. © 2026 Obsidian Genetics. All rights reserved.